|
coronavirus |
11 |
|
influenza |
11 |
|
public health |
11 |
|
transmission |
11 |
|
airborne |
9 |
|
contamination |
9 |
|
influenza virus |
9 |
|
influenza-virus |
9 |
|
antibody-dependent cellular cytotoxicity |
8 |
|
baseline immunity |
8 |
|
ha stem antibodies |
8 |
|
influenza virus infection |
8 |
|
t cells |
8 |
|
universal immune correlate |
8 |
|
antibody |
7 |
|
asymptomatic |
7 |
|
epidemiology |
7 |
|
vaccination |
7 |
|
viral shedding |
7 |
|
children |
6 |
|
environment |
6 |
|
school |
6 |
|
surface |
6 |
|
adjuvant |
5 |
|
antibodies, viral - metabolism |
5 |
|
antibody-dependent enhancement |
5 |
|
b cell |
5 |
|
china |
5 |
|
ha stem |
5 |
|
infection |
5 |
|
lymphocytes - virology |
5 |
|
membrane glycoproteins - metabolism |
5 |
|
receptors, igg - metabolism |
5 |
|
adult |
4 |
|
aged |
4 |
|
antimicrobial resistance |
4 |
|
clinical trials |
4 |
|
cohort analysis |
4 |
|
controlled study |
4 |
|
coronavirus disease 2019 |
4 |
|
covid‐19 |
4 |
|
daily life activity |
4 |
|
fomite |
4 |
|
guangdong |
4 |
|
hemagglutinin-stalk |
4 |
|
indirect contact |
4 |
|
infectious diseases |
4 |
|
intensive care unit |
4 |
|
mobile phone |
4 |
|
mode of transmission |
4 |
|
object |
4 |
|
one health |
4 |
|
pollution |
4 |
|
reactogenicity |
4 |
|
sars-cov-2 |
4 |
|
sars‐cov‐2 |
4 |
|
seroprevalence |
4 |
|
slums |
4 |
|
t cell |
4 |
|
universal vaccine |
4 |
|
burden |
3 |
|
mortality |
3 |
|
aerosol |
2 |
|
aerosols |
2 |
|
biomarkers |
2 |
|
droplet |
2 |
|
fc receptors. |
2 |
|
healthcare settings |
2 |
|
human |
2 |
|
infection control |
2 |
|
influenza - transmission |
2 |
|
influenza transmission |
2 |
|
influenza vaccines |
2 |
|
nosocomial infections |
2 |
|
prevention and control |
2 |
|
respiratory viruses |
2 |
|
sars (disease) - immunological aspects. |
2 |
|
terminology as topi |
2 |
|
viral aerosols |
2 |
|
viruses - receptors |
2 |
